Tyra Biosciences, Inc. (TYRA) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Tyra Biosciences, Inc.
Address
2656 State Street
Carlsbad, CA 92008
United States of America (the)
Phone
619 728 4760
Website
Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
September 15, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Todd Harris | Co-Founder, CEO, President & Director | 998,960 | 1979 |
| Ronald V. Swanson | Chief Scientific Officer | 536,188 | 1963 |
| Bhavesh Ashar | Chief Operating Officer | 551,017 | 1969 |
| Ali D. Fawaz | General Counsel & Secretary | 629,230 | N/A |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 737,643 | 1975 |
| Alan Fuhrman | Chief Financial Officer | 763,093 | 1957 |
| Douglas Warner | Chief Medical Officer | 764,683 | 1972 |
| Robert L. Hudkins | Chief Technology Officer | 0 | 1955 |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 0 | 1986 |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy | 0 | N/A |
Description
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
